Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment.

Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC.

Int J Med Sci. 2010 Jan 22;7(1):36-42.

2.

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.

Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD.

World J Gastroenterol. 2015 May 28;21(20):6236-45. doi: 10.3748/wjg.v21.i20.6236.

3.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

4.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
5.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579.

PMID:
18834319
6.

The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.

Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC.

Braz J Infect Dis. 2015 Jan-Feb;19(1):15-22. doi: 10.1016/j.bjid.2014.08.002. Epub 2014 Sep 1.

7.

Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.

Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, Aljudaibi BM.

Saudi J Gastroenterol. 2013 Sep-Oct;19(5):223-9. doi: 10.4103/1319-3767.118133.

8.

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.

Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.

J Viral Hepat. 2008 Aug;15(8):591-9. doi: 10.1111/j.1365-2893.2008.00988.x. Epub 2008 May 14.

PMID:
18482284
9.

Feasibility of individualized treatment for hepatitis C patients in the real world.

Chen TM, Huang PT, Lin CH, Tsai MH, Lin LF, Liu CC, Ho KS, Tung JN.

J Gastroenterol Hepatol. 2010 Jan;25(1):61-9. doi: 10.1111/j.1440-1746.2009.05946.x. Epub 2009 Sep 25.

PMID:
19780879
10.

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.

Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES.

Gastroenterology. 2013 Oct;145(4):790-800.e3. doi: 10.1053/j.gastro.2013.06.051. Epub 2013 Jun 26.

PMID:
23811112
11.

Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population.

Dahlan Y, Ather HM, Al-ahmadi M, Batwa F, Al-hamoudi W.

World J Gastroenterol. 2009 Sep 21;15(35):4429-33.

12.

Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.

Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M.

Antivir Ther. 2015;20(1):39-48. doi: 10.3851/IMP2781. Epub 2014 May 15.

PMID:
24831457
13.
14.

Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.

Kawaguchi Y, Iwane S, Kumagai T, Yanagita K, Yasutake T, Ide Y, Otsuka T, Eguchi Y, Ozaki I, Akiyama T, Kawazoe S, Mizuta T.

Intern Med. 2015;54(20):2551-60. doi: 10.2169/internalmedicine.54.4817. Epub 2015 Oct 15.

15.

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.

J Hepatol. 2010 Apr;52(4):501-7. doi: 10.1016/j.jhep.2010.01.016. Epub 2010 Feb 4.

PMID:
20189674
16.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.

PMID:
18503773
17.

Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.

Harrison SA, Abdurakhmanov D, Shiffman ML, Bakulin I, Mazur W, Rodriguez-Torres M, Silva GF, Cheinquer H, Messinger D, Connell EV, McKenna M, Tatsch F, Reddy KR; PROGRESS Investigators.

J Clin Gastroenterol. 2013 Mar;47(3):271-9. doi: 10.1097/MCG.0b013e31826102eb.

PMID:
22951527
18.

Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.

Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS.

Antimicrob Agents Chemother. 2014;58(2):1136-45. doi: 10.1128/AAC.01515-13. Epub 2013 Dec 2.

19.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators.

N Engl J Med. 2007 Jul 12;357(2):124-34.

20.

A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.

Selvapatt N, Habibi MS, Brown A.

J Med Virol. 2015 Oct;87(10):1716-21. doi: 10.1002/jmv.24228. Epub 2015 Apr 24.

PMID:
25914248

Supplemental Content

Support Center